New study tests inhaled steroid safety in fragile preemies
NCT ID NCT06589245
First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 23 times
Summary
This early-stage study tests the safety of an inhaled steroid (ciclesonide) in 30 premature babies who are on breathing machines and at risk for a chronic lung condition called bronchopulmonary dysplasia. Researchers will monitor side effects like high blood sugar, growth changes, and adrenal function, and measure how much of the drug enters the bloodstream. The goal is to see if this treatment can be safely used to help prevent lung damage in these vulnerable infants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHOPULMONARY DYSPLASIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Mercy Kansas City
RECRUITINGKansas City, Missouri, 64108, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.